Furthermore, gemcitabine in combination with radiotherapy has shown clinical benefit in lung and pancreatic cancer [41,42] and these data suggests that addition of an ATR inhibitor to such trials may prove beneficial in several types of cancer independently of p53 status. This evidence concerns the gene TP53 and familial pancreatic carcinoma.